# Development of Human Anthrax Immune Globulin

> **NIH NIH N01** · EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR · 2021 · $749,260

## Abstract

The Development of the Human Anthrax Immune Globulin (AIGIV) contract supports studies to assess the efficacy of anthrax immune globulin for intravenous use (AIGIV) as a therapeutic for anthrax disease.

## Key facts

- **NIH application ID:** 10428337
- **Project number:** 272200700034C-P00006-9999-1
- **Recipient organization:** EMERGENT PRODUCT DEVELOPMENT GAITHERSBUR
- **Principal Investigator:** HOPKINS ROBERT
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $749,260
- **Award type:** —
- **Project period:** 2007-09-28 → 2011-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10428337

## Citation

> US National Institutes of Health, RePORTER application 10428337, Development of Human Anthrax Immune Globulin (272200700034C-P00006-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10428337. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*